046210 fundamentals

HLB PANAGENE Co., Ltd. engages in the molecular diagnostics business. The firm is also involved in the development, manufacturing, and sale of peptide nucleic acid (PNA) genetic diagnostic chips. It operates through the following business divisions: PNA Materials, PNAClamp, PANAMutyper, OncoTector, PANA RealTyper, PANA qPCR, Nucleic Acid Extraction Equipment, Nucleic Acid Extraction Reagent, and Immunodiagnosis. The PNA Materials business division includes materials for molecular diagnostic reagents. The PNAClamp business division focuses on the detection of somatic mutations in lung, colon, thyroid, blood, thyroid, and breast cancers, as well as brain tumors. The PANAMutyper business division is composed of liquid biopsy and tissue somatic detection for lung cancer and chemotherapy prescription. The OncoTector business division pertains to BRAF and KRAS inhibitor companion diagnostic product for lung cancer. The PANA RealTyper business division consists of strain testing for sexually transmitted pathogen and antibiotic resistance, as well as HPV genotyping test and vaccine prescription for cervical cancer. The PANA qPCR business division offers tuberculosis test. The Nucleic Acid Extraction Equipment business division provides equipment for nucleic acid extraction. The Nucleic Acid Extraction Reagent business division refers to DNA and RNA extraction reagent for paraffin-embedded tissue, virus and bacteria extraction reagent for nucleic acids, blood-derived nucleic acid extraction reagent, nucleic acid extraction reagent derived from cell free DNA, cell-derived nucleic acid extraction reagent, and tissue origin nucleic acid extraction reagent. The Immunodiagnosis business division offers tests for influenza, corona, and respiratory syncytial viruses. The company was founded on July 7, 1976 and is headquartered in Daejeon, South Korea.